Department of Medicine, Massachusetts General Hospital & Harvard Medical School, Boston, MA 02114, USA.
Future Oncol. 2017 Aug;13(18):1649-1663. doi: 10.2217/fon-2017-0117. Epub 2017 Aug 4.
Recent advances in the use of immunotherapy have led to historic advancements in the field of oncology. Checkpoint inhibitors have demonstrated significant effectiveness against a broadening range of cancers. However, despite the success of antibodies against the immune regulators, CTLA4 and PD-L1/PD-1, only a subset of patients will have a durable response to these therapies, which implies that a broader view of cancer immunity is required. It is becoming increasingly apparent that combination therapy to target multiple events in the cancer-immunity cycle is needed and could potentially extend the benefit of immunotherapy to a larger population. In this review, we discuss the current status of immunotherapy and highlight the use of combination therapy to prime the tumor microenvironment and thereby improve treatment effect.
免疫疗法的最新进展引领了肿瘤学领域的历史性进步。检查点抑制剂在对抗不断扩大的癌症范围方面显示出显著的疗效。然而，尽管针对免疫调节剂 CTLA4 和 PD-L1/PD-1 的抗体取得了成功，但只有一部分患者会对这些治疗产生持久的反应，这意味着需要更广泛地了解癌症免疫。越来越明显的是，需要针对癌症免疫周期中的多个事件进行联合治疗，这有可能将免疫疗法的益处扩展到更大的人群。在这篇综述中，我们讨论了免疫疗法的现状，并强调了联合治疗在激活肿瘤微环境方面的应用，从而提高治疗效果。
